<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363074">
  <stage>Registered</stage>
  <submitdate>24/09/2012</submitdate>
  <approvaldate>28/09/2012</approvaldate>
  <actrnumber>ACTRN12612001039875</actrnumber>
  <trial_identification>
    <studytitle>Therapeutic efficacy study of artemether-lumefantrine and artesunate-amodiaquine in the treatment of uncomplicated  Plasmodium falciparum malaria at two sentinel sites in Togo</studytitle>
    <scientifictitle>Therapeutic efficacy study of artemether-lumefantrine and artesunate-amodiaquine in the treatment of uncomplicated  Plasmodium falciparum malaria at two sentinel sites in Togo</scientifictitle>
    <utrn>none</utrn>
    <trialacronym>none</trialacronym>
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>uncomplicated falciparum malaria</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Studies of infection and infectious agents</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Artemether-lumefantrine tablets, each containing 20 mg of artemether and 120 mg of lumefantrine, will be administered twice daily for 3 consecutive days. Children with body weight of 5-14 kg will receive one tablet morning and evening and chidren from 15 kg up to 24 kg will received 2 tablets morning and evening. Patients treated with artesunate plus amodiaquine will be administered oral tablets of artesunate at a dose of 4 mg/kg/day up to a maximum of 250 mg per day and oral tablets of amodiaquine at a dose of 10/kg/day up to a maximum of 600 mg per day for three consecutive days.  Patients will be observed for 28 days follwoing initiation of treatment.  Artemether-lumefantrine and artesunate plus amodiaquine treatments correspond to the first and second line antimalarial treament policy (standard of care) in Togo, respectivlely.</interventions>
    <comparator>Uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PCR adjusted adequate clinical and parasitological response at Day 28 (percent of treatment failures (early + late clinical failure + late parasitological failureas defined in the latest WHO protocol for monitoring therapeutic efficacy of antimalarial drugs.</outcome>
      <timepoint>Day 28 following initiation of treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent of adverse events will be documented. Possible  adverse events, related or not to the medicines, include dizziness, itching, vomiting abdominal pain, flatulence, headache, bodyache, diarrhoea, tinnitus, increased hair loss, macular rash, reduction in neurophil counts, convulsions</outcome>
      <timepoint>Day 28 following initiation of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age between 6 and 59 months 
microscopically confirmed monoinfection with P falciparum
parasitemia (asexual forms) between 2000 and 200 000 per microliter
fever (body temperature of 37.5 C or greater)
able to swallow medication
able to comply with protocol assessment schedule</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>59</inclusivemaxage>
    <inclusivemaxagetype>Months</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>clinical signs and symptoms of severe malaria
infection with another Plasmodium species or co-infection
severe malnutrition
fever due to other diseases</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration />
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>24/09/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>450</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Togo</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministere de la Sante du Togo</primarysponsorname>
    <primarysponsoraddress>Angle Avenue du 24 Janvier et avenue Sarakawa</primarysponsoraddress>
    <primarysponsorcountry>Togo</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>World Health Organisation</fundingname>
      <fundingaddress>20 Avenue Appia
CH1211 Geneva</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To monitor the efficacy and safety of artemether-lumefantrine and artesunate amodiaquine in the treatment of uncomplicated falciparum malaria in two sentinel sites in Togo</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WHO ERC</ethicname>
      <ethicaddress>20 Avenue Appia 
CH1211 
Geneva</ethicaddress>
      <ethicapprovaldate>12/09/2012</ethicapprovaldate>
      <hrec>RPC536</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr AM Dorkendoo</name>
      <address>Medicine and Pharmacy Faculty
Universtiy of Lome
BP 1515 Lome</address>
      <phone>+228 90 04 44 17</phone>
      <fax />
      <email>monicadork@yahoo.fr</email>
      <country>Togo</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr AM Dorkendoo</name>
      <address>Medicine and Pharmacy Faculty
Universtiy of Lome
BP1515 Lome</address>
      <phone>+228 90 04 44 17</phone>
      <fax />
      <email>monicadork@yahoo.fr</email>
      <country>Togo</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alison Osborne</name>
      <address>20 Avenue Appia
CH1211 Geneva</address>
      <phone>+41 22 791 2782</phone>
      <fax />
      <email>osbornea@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>